C18

Small molecule CFTR corrector

Phase of research

Pre-clinical

How it helps

Restore CFTR Function

General information

C18 is a small-molecule CFTR corrector discovered by Vertex Pharmaceuticals. It is an experimental substance used in studies and not yet available as a human pharmaceutical. In relation to cystic fibrosis, our AIM tool found the data that C18 can correct various CFTR mutations.

Synonyms

N/A

Marketed as

N/A

Dietary sources

N/A

Structure image not available

N/A

Drug-Mutation Relation

results for D1152H / F508del

See all data on C18

Treats

Mutation	Link	Tested on	Impact factor	Notes
F508del	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics	human cell cultures	2.81	Better in combination with PYR-41.
F508del	Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis	human cell cultures	N/A

Does not treat

Mutation	Link	Tested on	Impact factor	Notes